Literature DB >> 23711418

Quantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals.

A Kahlon1, J Grabell, A Tuttle, D Engen, W Hopman, D Lillicrap, P James.   

Abstract

von Willebrand's disease (VWD) patients undergoing major surgery are prophylactically treated to promote haemostasis. There is variability in perioperative clinical practice; however, most guidelines suggest replacing the deficient factor to a level of 1.0 IU mL(-1) (or 100%). A review of the literature reveals a paucity of well constructed descriptive data quantifying the changes in coagulation that occur in response to surgical stress. The aim of this study was to quantify the changes in haemostatic variables occurring in response to elective orthopaedic surgery in normal individuals. Eligible subjects >18 years of age undergoing total hip or knee replacement were recruited. Blood samples were drawn at five time points: baseline, preoperatively, 30 min after surgical incision, 30 min postoperatively, postoperative day (POD) 1. Analyses included t-tests and repeated measures anova. Overall 30 patients, 21 women and 9 men, with a mean age of 65 were included in the final analysis. All von Willebrand factor (VWF) variables were seen to significantly decrease intraoperatively and increase postoperatively. VWF multimers showed a statistically significant decrease in high molecular weight multimers intraoperatively and an increase postoperatively. On subgroup analysis, age, gender and anaesthesia type were significantly correlated with changes in VWF parameters. Data presented in the current study establish a physiological baseline for VWF parameters in the normal population and demonstrate mean VWF/factor VIII levels greater than 1.0 IU mL(-1) intraoperatively. As such, current management in VWD patients does not appear to mimic the normal physiological response to surgery.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  factor VIII; surgery; von Willebrand factor

Mesh:

Substances:

Year:  2013        PMID: 23711418      PMCID: PMC4164434          DOI: 10.1111/hae.12185

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  27 in total

1.  A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma.

Authors:  R M HARDISTY; J C MACPHERSON
Journal:  Thromb Diath Haemorrh       Date:  1962-05-15

Review 2.  Treatment of von Willebrand's Disease.

Authors:  Pier Mannuccio Mannucci
Journal:  N Engl J Med       Date:  2004-08-12       Impact factor: 91.245

3.  Physical stress as a model to study variations in ADAMTS-13 activity, von Willebrand factor level and platelet activation.

Authors:  R A Claus; C L Bockmeyer; M Sossdorf; W Lösche; T Hilberg
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

Review 4.  Wound healing in haemophilia--breaking the vicious cycle.

Authors:  M Hoffman; D M Monroe
Journal:  Haemophilia       Date:  2010-05       Impact factor: 4.287

5.  Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.

Authors:  Pier M Mannucci; Juan Chediak; Wahid Hanna; John Byrnes; Marlies Ledford; Bruce M Ewenstein; Anastassios D Retzios; Barbara A Kapelan; Richard S Schwartz; Craig Kessler
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

6.  von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.

Authors:  J C Gill; A Shapiro; L A Valentino; J Bernstein; C Friedman; W L Nichols; M Manco-Johnson
Journal:  Haemophilia       Date:  2011-04-27       Impact factor: 4.287

7.  Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes.

Authors:  U Budde; R Schneppenheim; H Plendl; J Dent; Z M Ruggeri; T S Zimmerman
Journal:  Thromb Haemost       Date:  1990-04-12       Impact factor: 5.249

8.  Prevalence of von Willebrand disease in children: a multiethnic study.

Authors:  E J Werner; E H Broxson; E L Tucker; D S Giroux; J Shults; T C Abshire
Journal:  J Pediatr       Date:  1993-12       Impact factor: 4.406

9.  Epidemiological investigation of the prevalence of von Willebrand's disease.

Authors:  F Rodeghiero; G Castaman; E Dini
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

10.  Fainting induces an acute increase in the concentration of plasma factor VIII and von Willebrand factor.

Authors:  Alessandra Casonato; Elena Pontara; Antonella Bertomoro; Maria Grazia Cattini; Carmen Soldera; Antonio Girolami
Journal:  Haematologica       Date:  2003-06       Impact factor: 9.941

View more
  6 in total

1.  A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.

Authors:  Hendrika Hazendonk; Karin Fijnvandraat; Janske Lock; Mariëtte Driessens; Felix van der Meer; Karina Meijer; Marieke Kruip; Britta Laros-van Gorkom; Marjolein Peters; Saskia de Wildt; Frank Leebeek; Marjon Cnossen; Ron Mathôt
Journal:  Haematologica       Date:  2016-07-06       Impact factor: 9.941

2.  Pharmacokinetic-guided dosing of factor VIII concentrate in a patient with haemophilia during renal transplantation.

Authors:  Hendrika C A M Hazendonk; Marieke J H A Kruip; Ron A A Mathôt; Marjon H Cnossen
Journal:  BMJ Case Rep       Date:  2016-09-22

3.  Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa.

Authors:  Pablo Rendo; Janice Lamb; Lynne Smith; Joanne Fuiman; Joan M Korth-Bradley
Journal:  Blood Coagul Fibrinolysis       Date:  2018-01       Impact factor: 1.276

4.  Impact of Arterial Procedures on Coagulation and Fibrinolysis - A Pilot Study.

Authors:  Kamil Jurand Polok; Jacek Górka; Jakub Fronczek; Karolina Górka; Bogusz Kaczmarek; Teresa Iwaniec; Paweł Iwaszczuk; Jacek Musiał; Wojciech Szczeklik
Journal:  Braz J Cardiovasc Surg       Date:  2019-06-01

5.  Bleeding assessment tools to predict von Willebrand disease: Utility of individual bleeding symptoms.

Authors:  Jordan Spradbrow; Sasha Letourneau; Julie Grabell; Yupu Liang; James Riddel; Wilma Hopman; Victor S Blanchette; Margaret L Rand; Barry S Coller; Andrew D Paterson; Paula D James
Journal:  Res Pract Thromb Haemost       Date:  2019-10-30

6.  Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders.

Authors:  Jerzy Windyga; Benoît Guillet; Lucia Rugeri; Alexandra Fournel; Ewa Stefanska-Windyga; Valérie Chamouard; Sonia Pujol; Céline Henriet; Françoise Bridey; Claude Négrier
Journal:  Thromb Haemost       Date:  2022-05-31       Impact factor: 6.681

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.